GENELUX Corp SEC filings GNLX
GENELUX Corp has 362 filings in SEC EDGAR's recent list, going back to May 5, 2003. Its latest annual report, Form ARS, was filed on Apr 29, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 13, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Jun 22, 2026 (shareholder vote results). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Shareholder vote results
|
Jun 22, 2026 | Jun 16, 2026 |
| 8-K |
Current report
Material agreement
|
Mar 19, 2026 | Mar 19, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Feb 2, 2026 | Feb 2, 2026 |
| 8-K |
Current report
Other events
|
Jan 8, 2026 | Jan 8, 2026 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Jan 5, 2026 | Jan 5, 2026 |
| 8-K |
Current report
Officer or director change
|
Jan 2, 2026 | Dec 30, 2025 |
| 8-K |
Current report
Officer or director change, Shareholder vote results
|
Sep 3, 2025 | Aug 27, 2025 |
| 8-K |
Current report
Other events
|
Mar 25, 2025 | Mar 25, 2025 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure, Other events
|
Mar 25, 2025 | Mar 25, 2025 |
| 8-K |
Current report
Officer or director change
|
Feb 3, 2025 | Jan 29, 2025 |
| 8-K |
Current report
Regulation FD disclosure
|
Nov 8, 2024 | Nov 8, 2024 |
| 8-K |
Current report
Officer or director change
|
Oct 3, 2024 | Sep 23, 2024 |
| 8-K |
Current report
Shareholder vote results
|
Aug 6, 2024 | Aug 1, 2024 |
| 8-K |
Current report
Regulation FD disclosure
|
Aug 1, 2024 | Aug 1, 2024 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Jun 5, 2024 | Jun 3, 2024 |
| 8-K |
Current report
Material agreement, Regulation FD disclosure, Other events
|
May 24, 2024 | May 23, 2024 |
| 8-K |
Current report
Regulation FD disclosure
|
Apr 9, 2024 | Apr 9, 2024 |
| 8-K |
Current report
Regulation FD disclosure
|
Apr 2, 2024 | Apr 1, 2024 |
| 8-K |
Current report
Regulation FD disclosure
|
Feb 5, 2024 | Feb 5, 2024 |
| 8-K |
Current report
Results of operations, Other events
|
Feb 2, 2024 | Feb 2, 2024 |
| 8-K |
Current report
Regulation FD disclosure
|
Dec 12, 2023 | Dec 12, 2023 |
| 8-K |
Current report
Officer or director change
|
Nov 24, 2023 | Nov 21, 2023 |
| 8-K |
Current report
Regulation FD disclosure
|
Oct 10, 2023 | Oct 10, 2023 |
| 8-K |
Current report
Officer or director change, Shareholder vote results
|
Sep 14, 2023 | Sep 11, 2023 |
| 8-K |
Current report
Officer or director change
|
Aug 28, 2023 | Aug 28, 2023 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Jul 19, 2023 | Jul 18, 2023 |
| 8-K |
Current report
Listing notice, Officer or director change
|
Jul 14, 2023 | Jul 10, 2023 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Jun 27, 2023 | Jun 27, 2023 |
| 8-K |
Current report
Material agreement, Unregistered share sale
|
Jun 12, 2023 | Jun 9, 2023 |
| 8-K |
Current report
Officer or director change
|
Jun 2, 2023 | May 30, 2023 |
| 8-K |
Current report
Officer or director change, Bylaw or fiscal year change, Other events
|
Jan 30, 2023 | Jan 30, 2023 |
Showing 31 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- GNLX (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Westlake Village, CA
- SEC filer status
- Non-accelerated filer, Smaller reporting company, Emerging growth company
- SEC CIK
- 1231457
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.